Clinical study on the screening of biomarkers for Crohn’s disease based on blood metabolomics
Tongyuan Lin, Xianhong Hu, Kaifei Yuan, SiYuan Li, Ping Lin, Wei Wang, Li Cui, YuanYuan Wang, Ping Liu, Yong Yang · 2026
Read Clinical study on the screening of biomarkers for Crohn’s disease based on blood metabolomics by Tongyuan Lin, Xianhong Hu, Kaifei Yuan, SiYuan Li, Ping Lin, Wei Wang, Li Cui, YuanYuan Wang, Ping Liu, Yong Yang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13441770.txt.
Description
Tongyuan Lin and colleagues profile blood metabolites in Crohn's disease patients on biologic drugs, hunting for markers that track treatment response, in a 2026 study. Diagnosis still leans on invasive scopes and tissue reading, and how biologics reshape metabolism was little studied. Eighty-one patients on infliximab or ustekinumab at week sixteen joined forty-five healthy controls. High-end chromatography and mass spectrometry catalogued their blood chemistry.
Both drug groups sat in clinical remission, yet their inflammation markers still ran above healthy levels. Each drug left a distinct metabolic fingerprint: infliximab touched amino acid pathways and core energy cycles, while ustekinumab touched glutathione and purine pathways. Arginine and kindred metabolites tracked with clinical indicators in correlation analysis. The authors argue that blood metabolite panels could complement scopes for judging whether a biologic is truly working.
Catalog record
| CREATOR | Tongyuan Lin, Xianhong Hu, Kaifei Yuan, SiYuan Li, Ping Lin, Wei Wang, Li Cui, YuanYuan Wang, Ping Liu, Yong Yang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53302 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |